Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 GlobeNewswire December 01, 2025 Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that […]

Rush Street Interactive Named Operator of the Year-North LatAm at the EGR LatAm Awards GlobeNewswire December 01, 2025 CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Rush Street Interactive, Inc. (NYSE: RSI) (“RSI”), a leading online casino and sports betting company in the United States and the rest of the Americas, is proud to announce that

Brian Lanktree to Join Raven Capital as Senior Managing Director and Head of Capital Solutions GlobeNewswire December 01, 2025 LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) — Raven Capital (“Raven”), an alternative investment firm specializing in asset-based, non-sponsor private credit, today announced that Brian Lanktree has been named Senior Managing Director and Head of Capital

The Energy Breakthrough That Could Power the AI Era GlobeNewswire December 01, 2025 This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 01, 2025 (GLOBE NEWSWIRE) — MiningNewsWire Editorial Coverage: Global electricity demand is entering a historic inflection point. The International Energy Agency

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference GlobeNewswire December 01, 2025 SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37th Annual Healthcare Conference to be

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ(TM)) in South Korea for the Treatment of Presbyopia Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ GlobeNewswire December 01, 2025 SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics,

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th GlobeNewswire December 01, 2025 MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath(R), a novel, FDA-cleared

Hudson Technologies Board of Directors Approves Increase in Share Repurchase Authorization GlobeNewswire December 01, 2025 WOODCLIFF LAKE, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced that its board of directors has approved an increase to the Company's share repurchase authorization. Hudson may now purchase up to $20 million in shares

DeFi Development Corp. Partners with Harmonic to Optimize Solana Validator Revenue and Network Participation GlobeNewswire December 01, 2025 BOCA RATON, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it has begun integrating

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP GlobeNewswire December 01, 2025 December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of